The FDA’s approval for the ‘other’ HPV-vaccine, Cervarix is still delayed. GlaxoSmithKline, the world’s second-largest drugmaker, requested a ‘priority’ review, potentially prompting an approval decision and sale of the Cervarix vaccine by the end of 2007, said James Tursi, Glaxo’s director of medical affairs for cervical cancer vaccines, at a medical meeting in San Diego.